Orchestra BioMed Holdings (OBIO) Profit After Tax (2021 - 2026)

Orchestra BioMed Holdings (OBIO) has 6 years of Profit After Tax data on file, last reported at -$20.7 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 10.32% year-over-year to -$20.7 million in Q1 2026; TTM through Mar 2026 was -$54.6 million, a 17.66% increase from a year earlier, with the FY2025 full-year figure at -$52.7 million, up 13.65% from the prior year.
• Profit After Tax for Q1 2026 stood at -$20.7 million, down from $6.3 million in the prior quarter.
• Over the last five years, Profit After Tax for OBIO reached as high as $6.3 million in Q4 2025 and fell as low as -$20.8 million in Q3 2025.
• Historically, Profit After Tax has averaged -$12.8 million across 5 years, with a median of -$13.3 million in 2023.
• Across the five-year window, Profit After Tax tumbled 11272.51% in 2022 and surged 138.49% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$9.8 million in 2022, then sank by 31.47% to -$12.8 million in 2023, then slipped by 26.88% to -$16.3 million in 2024, then jumped by 138.49% to $6.3 million in 2025, then plunged by 430.53% to -$20.7 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$20.7 million in Q1 2026, $6.3 million in Q4 2025, and -$20.8 million in Q3 2025.